{
"id":"mk19_a_id_q041",
"number":41,
"bookId":"id",
"correctAnswer":"B",
"title":"Question 41",
"stimulus":[
{
"type":"p",
"hlId":"10cfed",
"children":[
"A 42-year-old woman is evaluated for hepatitis B reactivation risk before deceased donor kidney transplantation for end-stage kidney disease. Medical history is significant for chronic hepatitis B and hypertension. Medications are labetalol, amlodipine, cholecalciferol, sevelamer, and sodium bicarbonate."
]
},
{
"type":"p",
"hlId":"921bbc",
"children":[
"On physical examination, vital signs are normal. A mature arteriovenous fistula is located over the right arm. Abdominal examination reveals no hepatomegaly."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"86ee9b",
"children":[
"Laboratory studies completed 1 week ago: "
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"62ea29",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Aminotransferase, alanine (ALT)",
"children":[
"Alanine aminotransferase"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9f462f",
"class":"cell text l",
"children":[
"10 U/L"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"8a077f",
"class":"cell text l",
"children":[
"HIV-1/2 antigen/antibody testing"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"2ff2e8",
"class":"cell text l",
"children":[
"Hepatitis B surface antigen"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"3a242b",
"class":"cell text l",
"children":[
"Hepatitis B surface antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"6e8ea5",
"class":"cell text l",
"children":[
"Hepatitis B core total antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"20cc3d",
"class":"cell text l",
"children":[
"Hepatitis B e antigen"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"aa7caf",
"class":"cell text l",
"children":[
"Hepatitis B e antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d6f262",
"class":"cell text l",
"children":[
"Hepatitis B DNA"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"8044e8",
"class":"cell text l",
"children":[
"920 U/mL"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"8c876d",
"children":[
"Ultrasound performed 1 month ago is negative for cirrhosis and hepatocellular carcinoma."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"62cb19",
"children":[
"Which of the following is the most appropriate management for this patient after transplantation?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Alanine aminotransferase monitoring"
}
},
{
"letter":"B",
"text":{
"__html":"Entecavir"
}
},
{
"letter":"C",
"text":{
"__html":"Hepatitis B adjuvant vaccine"
}
},
{
"letter":"D",
"text":{
"__html":"Hepatitis B immune globulin"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"ee675b",
"children":[
"Patients with chronic hepatitis B infection who will be receiving immunosuppressive therapy should begin antiviral therapy (entecavir or tenofovir) to prevent reactivation."
]
},
{
"type":"keypoint",
"hlId":"167771",
"children":[
"In patients with chronic hepatitis B infection, antiviral therapy should be initiated at the time of transplantation and be continued indefinitely afterward."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"2bde34",
"children":[
"Entecavir is the most appropriate management of this patient's chronic hepatitis B virus (HBV) after transplantation (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). She is at very high risk for hepatitis B reactivation immediately following transplantation owing to immunosuppressive therapy to prevent rejection of the transplanted organ. Because of the high risk of reactivation, patients with chronic HBV infection (hepatitis B surface antigen positivity for >6 months) who will be receiving immunosuppressive therapy, including immunosuppression immediately after solid organ transplantation, should begin potent antiviral therapy (entecavir or tenofovir) directed against HBV. Therapy should be initiated at the time of transplantation and be continued indefinitely afterward. Although this patient was likely in the immune control phase (normal alanine aminotransferase level, low hepatitis B DNA [<2000 U/mL]), negative hepatitis e antigen) before transplantation and did not require therapy, her risk for reactivation now is high, and entecavir should be started."
]
},
{
"type":"p",
"hlId":"66aa3a",
"children":[
"Without antiviral therapy, some studies have shown that the risk of HBV reactivation in kidney transplant recipients who are hepatitis B surface antigen positive could be 50% to 94%. Therefore, monitoring the alanine aminotransferase level alone in a high-risk situation is inadequate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
")."
]
},
{
"type":"p",
"hlId":"130510",
"children":[
"Hepatitis B vaccination and immune globulin are used to prevent HBV infection in nonimmune persons (negative surface antigen and negative surface antibody) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C, D"
]
},
"). They are unlikely to help this patient. If a patient undergoing pretransplant evaluation had not been vaccinated against HBV and serology showed nonimmune status, then vaccination is strongly recommended. Hepatitis B immune globulin is primarily used in postexposure prophylaxis when a susceptible person has had high-risk exposure to HBV. It has also been used in some liver transplant recipients whose liver disease was related to chronic hepatitis B and whose transplanted liver was from an uninfected donor."
]
}
],
"relatedSection":"mk19_a_id_s16_3_2_1",
"objective":{
"__html":"Prevent hepatitis B reactivation in a patient undergoing immunosuppressive therapy."
},
"references":[
[
"Te H, Doucette K. Viral hepatitis: guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant. 2019;33:e13514. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30817047",
"target":"_blank"
},
"children":[
"PMID: 30817047"
]
},
" doi:10.1111/ctr.13514"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":26,
"B":58,
"C":4,
"D":13,
"E":0
},
"hlIds":[
"10cfed",
"921bbc",
"86ee9b",
"62ea29",
"9f462f",
"8a077f",
"ffb935",
"2ff2e8",
"328929",
"3a242b",
"ffb935",
"6e8ea5",
"328929",
"20cc3d",
"ffb935",
"aa7caf",
"328929",
"d6f262",
"8044e8",
"8c876d",
"62cb19",
"ee675b",
"167771",
"2bde34",
"66aa3a",
"130510"
]
}